Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies

Husheng Mei(University of Science and Technology of China), Qingsong Liu(Medical College of Wisconsin), Jing Yang(Yangzhou Polytechnic Institute), Shuang Qi(People's Liberation Army No. 150 Hospital), Yongfei Chen(Chinese Academy of Sciences), Wenchao Wang(Chinese Academy of Sciences), Bin Zhou(Second Affiliated Hospital of Nanjing Medical University), Beilei Wang(Northwestern Polytechnical University), Chen Hu(Jiangsu University), Fengming Zou(Chinese Academy of Sciences), Hong Wu(Chinese Academy of Sciences), Jing Liu(Chinese Academy of Sciences), Aoli Wang(Anhui University), Feiyang Liu(National University of Defense Technology), Zongru Jiang(University of Science and Technology of China)
Signal Transduction and Targeted Therapy
January 16, 2023
10.1038/s41392-022-01240-3
Cited by 46

Related Papers

Systematic identification of genomic markers of drug sensitivity in cancer cells
|Nature|2012|2.6k
A Landscape of Pharmacogenomic Interactions in Cancer
|Cell|2016|2.3k
Predictive values of neutrophil-to-lymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis
|Critical Care|2020|389
High salt primes a specific activation state of macrophages, M(Na)
|Cell Research|2015|243
Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma
|Cancer Research|2013|169